🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns ◆ Project Management Failures: Lessons for Healthcare ◆ FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli ◆ WeBuild Programme: 50+ Women-Led Ventures and How to Apply ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns ◆ Project Management Failures: Lessons for Healthcare ◆ FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli ◆ WeBuild Programme: 50+ Women-Led Ventures and How to Apply ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆
Clinical Trials in Denmark / NCT05150561
Active, not recruiting Observational

Muscle Dysfunction in Patients With Haematological Diseases

NCT05150561 · tracked via the Priya Life Science Denmark tracker
Sponsor
Copenhagen University Hospital, Rigshospitalet
Phase
Observational
Started
2023-10-01
Last updated
2026-08-14

Condition(s) studied

Hematologic DiseasesAcute Myeloid LeukemiaAcute Lymphoid LeukemiaMyelodysplastic SyndromesLymphoma

Study summary

PURPOSE: To evaluate the prevalence and prognostic value of sarcopenia in patients diagnosed with hematological cancer diseases.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: • Patients diagnosed with malignant lymphomas, acute leukaemia and multiple myeloma referred to treatment at the Department of Haematology, Rigshospitalet. Exclusion Criteria: * Age: \<18 * Pregnancy * Physical or mental disabilities precluding test of muscle function * Inability to read and understand Danish.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Rigshospitalet Copenhagen Denmark

Other trials for the same condition

Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant Active, not recruiting
Combining Active and Passive DNA Hypomethylation Recruiting
Autologous Transplantation of Human Cryopreserved Testis Tissue Active, not recruiting
REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs Recruiting
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05150561 on ClinicalTrials.gov ↗ ← All trials in Denmark